Figure 4.
Serum IgG levels after treatment with rozanolixizumab. (A) Mean serum IgG levels (pharmacodynamic per protocol set); arrows indicate time of rozanolixizumab subcutaneous infusion. *Minimum post-baseline mean. †Day when minimum post-baseline mean was achieved. (B) Percent change from baseline in serum IgG levels (pharmacodynamic per protocol set). Arrows indicate time of rozanolixizumab subcutaneous infusion.